Switching From Glargine to Degludec: The Effect on Metabolic Control and Safety During 1-Year of Real Clinical Practice in Children and Adolescents With Type 1 Diabetes

Background/Objective: Insulin degludec (IDeg) is an ultra-long-acting analog with less daily variability compared to other basal insulins. In this retrospective study we examined 1-year efficacy and safety of IDeg in youth with type 1 diabetes (T1D).Subjects/Methods: Thirty-seven patients [11.7 ± 4....

Full description

Bibliographic Details
Main Authors: Barbara Predieri, Tosca Suprani, Giulio Maltoni, Vanna Graziani, Patrizia Bruzzi, Stefano Zucchini, Lorenzo Iughetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-08-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fendo.2018.00462/full